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ABSTRACT  
 
Rationale: Atheroprogression is a consequence of non-resolved inflammation and currently a 
comprehensive overview of the mechanisms preventing resolution is missing. However, in acute 
inflammation, resolution is known to be orchestrated by a switch from inflammatory to resolving lipid 
mediators. Therefore we hypothesized that lesional lipid mediator imbalance favors atheroprogression. 
 
Objective: To understand the lipid mediator balance during atheroprogression and to establish an 
interventional strategy based on delivery of resolving lipid mediators. 
 
Methods and Results: Aortic lipid mediator profiling of aortas from Apoe-/- mice fed a high fat diet for four 
weeks, eight weeks, or four months revealed an expansion of inflammatory lipid mediators, Leukotriene 
B4 (LTB4) and Prostaglandin E2 (PGE2), and a concomitant decrease of resolving lipid mediators, 
Resolvin D2 (RvD2) and Maresin 1 (MaR1), during advanced atherosclerosis. Functionally, aortic LTB4 
and PGE2 levels correlated with traits of plaque instability while RvD2 and MaR1 levels correlated with 
signs of plaque stability. In a therapeutic context, repetitive RvD2 and MaR1 delivery prevented 
atheroprogression as characterized by halted expansion of the necrotic core and accumulation of 
macrophages along with increased fibrous cap thickness and smooth muscle cell numbers. Mechanistically, 
RvD2 and MaR1 induced a shift in macrophage profile towards a reparative phenotype which secondarily 
stimulated collagen synthesis in smooth muscle cells.       
 
Conclusions: We present evidence for the imbalance between inflammatory and resolving lipid mediators 
during atheroprogression. Delivery of RvD2 and MaR1 successfully prevented atheroprogression 
suggesting that resolving lipid mediators potentially represent an innovative strategy to resolve arterial 
inflammation. 
 
Keywords:  
Inflammation resolution, inflammation, atherosclerosis, lipid metabolites,  
 
Nonstandard Abbreviations and Acronyms:  
 
DHA  docosahexaenoic acid 
EPA  eicosapentaenoic acid 
HFD  high fat diet 
LTB4  Leukotriene B4 
MaR1  Maresin 1 
PG  Prostaglandin 
RvD2  Resolvin D2 
VPI  vulnerability plaque index  
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INTRODUCTION 
 
Atherosclerosis is a chronic inflammation of the arterial vessel wall that can lead to severe clinical 
events. In advanced atherosclerosis a series of mechanisms involved in inflammation resolution fail: (1) the 
recruitment of inflammatory leukocytes is continuous and (2) accompanied by macrophage proliferation, 
whose phenotype exhibits pro-inflammatory traits and (3) hampered efferocytic ability. The concomitant 
increase in accumulation of apoptotic cells builds up a necrotic core which is followed by fibrous cap 
thinning, further adding to plaque vulnerability and eventually leading to rupture1-4. Resolution of 
inflammation not only involves limiting the cellular traffic, but also removal of apoptotic cells (by 
efferocytosis), cell phenotype alterations, tissue healing and return to homeostasis. In accordance, several 
resolving lipid mediators, in particular Resolvin D2 (RvD2) and Maresin 1 (MaR1), have been reported to 
have an effect on macrophage phenotype, favoring M2 markers5, 6 and increasing efferocytic6, 7 and 
phagocytic capacity8, as well as increasing tissue regeneration7. Indeed with the identification of resolving 
lipid mediators the resolution process is no longer regarded as passive but rather dynamic9, opening a new 
window for therapeutic intervention. In this context, the strong potential of pro-resolution strategies in 
atherosclerosis was recently shown by administration of the Annexin A1-derived Ac2-26 fragment10, 11, a 
peptide that shares the FPR2 receptor with Resolvin D112. However, regarding resolving lipid mediators, 
their possible mode of action and a general comprehensive view in atherosclerosis are lacking, in particular 
for Resolvins of D-series and Maresins, which are recent members of the lipid mediator family. Overall 
clinical trials and animal studies report on atheroprotective traits of Omega-3 fatty acids, particularly of 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the precursors of most resolving lipid 
mediators, namely lipid-lowering effects, and reduced lesional accumulation of macrophages and foam cell 
numbers13-15. Indeed DHA, the precursor for Resolvins D1 and D2 (RvD2)16, 17 as well as Maresin 1 
(MaR1)8, reduces atherosclerosis in mice18 and plasma DHA levels associate with reduced 
atheroprogression in coronary arteries in humans19. Similarly, 12/15 lipoxygenase, the enzyme responsible 
for the synthesis of Lipoxin A4 (LXA4), RvD1 and MaR1 was also shown to be protective towards 
atherosclerosis20, setting the stage for the indication that progression of atherosclerosis may be a 
consequence of failed resolution21. Given the associative evidence for atheroprotective effects of the 
precursors of resolving lipid mediators, and more recently of Resolvin E1 in ApoE*3Leiden mice 22, we 
here hypothesized that atheroprogression may partly be explained by an imbalance of the arterial lipid 
mediator profile. Therefore we set to investigate how the balance of these mediators changes during the 
course of atherosclerosis, aiming at identifying relevant resolution-inducing candidates. Our data indicate 
that arterial levels of MaR1 and RvD2 decrease during atheroprogression and that delivery of these two 
lipid mediators promotes plaque stability. 
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METHODS 
 
Mice. 
Apoe-/- mice on C57Bl/6 background were fed a high-fat diet (HFD) containing 21% fat (ssniff) for 4 or 8 
weeks, 3 months, or 4 months as indicated in the respective experimental description. For treatment studies, 
after 3 months of HFD a combination of MaR1 and RvD2 (each 100 ng, i.p., every second day) or vehicle 
was administered during additional 4 weeks of HFD feeding. The doses for MaR1 and RvD2 were chosen 
based on previously published studies.23 All animal experiments were approved by the local ethical 
committee.  
 
Liquid chromatography/tandem mass spectrometry (LC-MS/MS). 
Aortic lipid mediators were measured by LC-MS/MS as previously described24. 
 
Statistics. 
All data are expressed as mean±SEM. Statistical calculations were performed using GraphPad Prism 5 
(GraphPad Software Inc.). After calculating for normality by D`Agostino Pearson omnibus test, unpaired 
Student’s t-test, one-way ANOVA with Tukey’ multiple comparison test, Mann Whitney test, Wilcoxon 
Signed-rank test, and Pearsons correlations were used as specified in each figure legend.  
 
For detailed Materials and Methods, please consult the supplemental materials. 
 
 
 
RESULTS 
 
Atheroprogression is characterized by imbalance of inflammatory and resolving lipid mediators.  
 
Apoe-/- mice were fed a high fat diet (HFD) for four weeks, eight weeks, or four months, thus 
allowing for development of early25 and advanced stages of atherosclerosis in mice26. To determine lipid 
mediator levels in atherosclerotic arteries at different stages of atherosclerosis, we subjected snap-frozen 
aortas from the Apoe-/- mice fed a HFD to LC-MS/MS analysis (Figure 1). At all three time points we 
detected inflammatory lipid mediators including Prostaglandins (PGE2, PGD2, PGA1, 15d-PGJ2, and 8iso-
PGA2), and Leukotriene B4 (LTB4). In addition, we could identify the resolution-inducing lipid mediators 
Resolvin D2 (RvD2) and Maresin 1 (MaR1), while Resolvin D1, Lipoxin A4, or Protectin Dx were below 
detection limit. Comparison of the measured lipid mediators during the course of atherosclerosis 
development showed a significant increase for most of the identified inflammatory lipid mediators with a 
4.5-fold increase of LTB4 and a 3-fold increase of PGE2 between the 4 weeks and the 4 months high fat 
diet (Figure 1A). In contrast, resolving lipid mediators significantly decreased with prolonged high fat diet 
feeding with a 5-fold decrease of RvD2 and a 2.5-fold decrease of MaR1 between the earlier and the later 
stage of atherosclerosis (Figure 1B/C). Together these data indicate that the progression of atherosclerosis 
in hypercholesterolemic mice is associated with an imbalance between inflammatory and resolving lipid 
mediators.  
 
Imbalance of aortic lipid mediators correlates with signs of plaque stability. 
 
To relate aortic lipid mediator signatures to characteristics of atherosclerotic lesions, we assessed 
signs of lesion stability in aortic root sections in Apoe-/- mice fed a high fat diet for four months and 
quantified lipid mediators in the aortas of the same mice. Herein, we measured lesion and necrotic core 
sizes, macrophages and smooth muscle cells, lesional collagen, and fibrous cap thickness. When integrating 
these parameters into a vulnerability plaque index (VPI), essentially a quotient of destabilizing 
(macrophages, necrotic core size) and stabilizing (smooth muscle cells, collagen) parameters, an integral 
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impression of plaque stability can be derived27. In addition, endothelial activation was assessed by 
measurement of ICAM1- and VCAM1-positive endothelial lining. 
 
When correlating lipid mediator levels with the VPI, we found a significant positive correlation for 
PGE2 and LTB4, whereas the correlation between VPI and RvD2 as well as MaR1 was found to be negative 
(Online Table I). No correlation was found for VPI and PGD2, PGA1, 15d-PGJ2, or 8iso-PGA2. When 
assessing individual plaque characteristics we observed that PGE2 and LTB4 primarily correlated with 
lesion size and macrophage accumulation (Figure 2A/B & Online Table I). In stark contrast, RvD2 and 
MaR1 correlated positively with the number of lesional smooth muscle cells, collagen deposition, and 
fibrous cap thickness (Figure 2C/D & Online Table I). In addition, RvD2 and MaR1 correlated negatively 
with necrotic core sizes. Thus, these data suggest that aortic levels of LTB4 and PGE2 associate with signs 
of plaque instability, while aortic RvD2 and MaR1 levels associate with signs of plaque stability.  
 
Administration of Resolvin D2 and Maresin 1 prevents atheroprogression. 
 
The decline of both RvD2 and MaR1 during advanced stages of atherosclerosis as well as the 
correlation of RvD2 and MaR1 with traits of plaque stability led us to question whether a combined 
therapeutic delivery of RvD2 and MaR1 would allow arresting plaque progression. Therefore, we subjected 
hypercholesterolemic Apoe-/- mice to an atheroprogression protocol (Figure 3A). Herein the baseline group 
was euthanized after three months of high fat diet feeding, time after which treatment was administered to 
the other two groups: a second group that received RvD2 and MaR1 (100 ng each, i.p., every second day) 
during a fourth month of high fat diet feeding, and a third group, treated with vehicle control instead. In 
mice receiving vehicle control, lesions increased in size and the VPI became progressively worse, a 
circumstance attributable to an expansion of the necrotic core and the accumulation of macrophages (Figure 
3B-I). In contrast, treatment with RvD2 and MaR1 halted atheroprogression as assessed by VPI. 
Immunohistomorphologically, treatment with resolving lipid mediators reduced the formation of the 
necrotic core, decreased plaque macrophage content and increased the numbers of smooth muscle cells 
(Figure 3B-I). In line with the latter are the significantly higher levels of total collagen in the group receiving 
lipid mediators (Figure 3D), possibly contributing to a thicker fibrous cap (Figure 3E). No difference was 
observed in endothelial VCAM1 or ICAM1 expression (Online Figure I). Treatment with RvD2 and MaR1 
did also not affect body weight, plasma lipid levels, nor blood cell counts as well as differential white cell 
counts in spleen, bone marrow, and lymph nodes (Online Figures II-V). Taken together, these data indicate 
that treatment with RvD2 and MaR1 suppresses atherosclerotic plaque progression. 
 
Resolvin D2 and Maresin 1 dampen macrophage-instructed inflammation. 
 
To address the mechanism of halted atheroprogression following MaR1/RvD2 treatment, we first 
assessed if the effect was systemic or local. Plasma levels of TNF, IL6, and IL13 were not significantly 
different between the two groups, whereas TGFβ was enhanced in the MaR1/RvD2-treated group (Online 
Figure VI). The latter finding may be supportive of pronounced lesional collagen deposition in these mice. 
In agreement with non-altered levels of inflammatory cytokines, the concentration of serum amyloid A, an 
acute phase protein, was not affected by MaR1/RvD2 administration (Online Figure VI). In addition, no 
changes in phenotypic markers on leukocyte subpopulations in the spleen, the bone marrow, and the blood 
were found (Online Table II). Together with unaltered leukocyte counts in blood, bone marrow, and spleen, 
these data suggest that the observed lesion phenotype does not primarily rely on a systemic but rather a 
local, lesion-inherent effect.  
 
Therefore, and to better understand the lesional microenvironment, we conducted a whole 
transcriptome analysis of aortic RNA extracts. Following bioinformatics analysis, we identified changes 
indicative of a macrophage M2 polarization in MaR1/RvD2-treated mice (Online Figure VII). To assess 
macrophage phenotypes in atherosclerotic lesions in more detail, we stained aortic root sections with 
 by guest on A
ugust 8, 2017
http://circres.ahajournals.org/
D
ow
nloaded from
 
 DOI: 10.1161/CIRCRESAHA.116.309492   6 
antibodies to inducible NO synthase (iNOS) and CD206, indicators of an inflammatory M1 or a reparative 
M2 polarization, respectively. When comparing aortic root section from mice receiving a HFD for 4 weeks 
with those of 4 months we evidence a clear decrease in the fraction of M2-polarized macrophages with a 
concomitant increase in M1 macrophage numbers (Online Figure VIII), thus shifting the balance between 
these polarization patterns. Comparison of lesions of mice receiving resolving lipid mediators with lesions 
from vehicle-treated mice then revealed a clear increase of the M2 macrophage fraction upon MaR1/RvD2 
treatment (Figure 4A). This phenotypic switch was further confirmed by qPCR of aortic RNA when 
quantifying Retnla (also known as Fizz1) and Nos2 (Figure 4B). The action of MaR1 and RvD2 on 
macrophage phenotype was additionally studied in vitro. Herein, macrophages were treated with TNF and 
IFNγ to generate a lesion-mimicking macrophage profile. Multiplex cytokine analysis showed that a 
combination of MaR1 and RvD2 decreased the secretion of TNF and IL6 by macrophages, while increasing 
that of TGFβ (Figure 4C). Gene expression studies confirmed the pro-resolving effect of these lipid 
mediators, revealing a decreased expression of Nos2 accompanied by enhanced expression of Arg1 and 
Tgfb1 (Figure 4D) in MaR1/RvD2-treated macrophages. 
 
As treatment of atherosclerotic mice with MaR1/RvD2 affected not only lesional macrophages but 
also smooth muscle cells and collagen deposition (Figure 3), we questioned whether the resolving lipid 
mediators act directly on smooth muscle cells or if the effect is rather mediated through macrophages. In 
vitro studies in aortic smooth muscle cells showed that the mRNA expression of genes related to collagen 
expression and maturation (Col1a1, Col3a1, P4ha1), as well as inflammation (Vcam1, Tgfb1) was not 
directly affected by MaR1/RvD2 treatment (Figure 4E). However, when aortic smooth muscle cells were 
treated with the supernatant of TNF-activated macrophages or of macrophages activated with TNF in 
presence of MaR1/RvD2, we observed an increase in mRNA levels of genes involved in collagen 
production (Col1a1, Col3a1) in smooth muscle cells receiving the supernatant harvested from reparative 
macrophages (Figure 4F). In line herewith, collagen production was found to be increased in aortic smooth 
muscle cells after treatment with the supernatant of reparative macrophages when compared to the treatment 
with inflammatory macrophages (Figure 4G). Interestingly, when blocking TGFβ receptor on smooth 
muscle cells much of the effect of the supernatant derived from reparative macrophages was lost indicative 
of the importance of macrophage-borne TGFβ during collagen production (Figure 4G). Altogether, these 
data suggest that in the present disease model, MaR1 and RvD2 locally act on macrophages, dampening 
the local inflammatory phenotype and favoring a pro-resolving milieu. This in turn acts on the surrounding 
smooth muscle cells and induces the production of collagen that stabilizes the atherosclerotic plaque. 
 
 
 
DISCUSSION 
 
Atheroprogression has long been regarded as a chronic inflammation however recent concepts also 
view atherosclerosis as a consequence of failed resolution3, 28. Resolution is crucially orchestrated by a 
switch from inflammatory to resolving lipid mediators in the affected tissue29, an event that is possibly 
impaired during atheroprogression.21 Here we show that as atherosclerosis progresses inflammatory lipid 
mediators overwhelm their resolving counterparts. In the current disease model, increased levels of LTB4 
and PGE2 directly correlate with plaque vulnerability whereas RvD2 and MaR1 are associated with plaque 
stability. With the decline of RvD2 and MaR1 during atheroprogression we chose to repetitively administer 
these lipid mediators as experimental therapeutic strategy. This setup allowed to halt atheroprogression as 
observed by reduced necrotic core sizes, thicker fibrous caps, and expansion of smooth muscle cells 
accompanied by reduction of macrophage accumulation. Central to this were changes in the macrophage 
profile from an inflammatory towards a reparative phenotype secondarily stimulating atheroprotective 
effects in smooth muscle cells (Online Figure IX).  
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In contrast to acute inflammatory situations, atheroprogression is characterized by the persistence 
of the initiating stimulus, including hypertension, hyperlipidemia, and oxidative stress3, 28. Interestingly, the 
synthesis of LTB4, driven by 5-lipoxygenase, depends on reactive oxygen species and is inhibited by nitric 
oxide30, a milieu typically prevailing in progressing atherosclerotic lesions. In addition, the local cytokine 
environment favors the accumulation of inflammatory over reparative macrophages31. LTB4 and PGE2 are 
produced in abundance at sites of inflammation32-34, suggesting their production by inflammatory 
macrophages. In accordance, metabololipidomic studies on human monocyte-derived macrophages show 
that M1 macrophages contain higher levels of LTB4 and PGE2, and, importantly, favor the synthesis of 
inflammatory lipid mediators, in comparison to their M2 counterpart.35 Thus, and albeit pro-resolving lipid 
mediators are being temporarily synthesized throughout the course of chronic inflammation, the arterial 
inflammatory milieu during atheroprogression crucially shapes the imbalance of arterial lipid mediators. 
Such an observation is also herein grounded by the prevailing M1 macrophage phenotype found in the 
atherosclerotic plaque of vehicle-treated mice, in comparison to the M2 phenotype found in MaR1/RvD2-
treated group as well as the content of reparative macrophages found within the lesion at early stages of the 
disease (mice subjected to HFD feeding for four weeks). Mechanistically, LTB4 potentiates atherosclerosis 
by increasing the expression of fatty acid translocase/CD36 and of CCL2 hereby inducing a positive feed-
back loop to recruit leukocytes36, 37. PGE2, as well as PGD2, on the other hand have been reported to have 
a dual, and paradoxical, role, functioning as pro-inflammatory and pro-resolving mediator, depending on 
its location.38 In the context of atherosclerosis, PGE2 is associated with disease progression, mediated by 
activation of platelets33 and consequently monocyte recruitment 39. In general lipid mediators are mostly 
produced by myeloid cells, where often the same cell can be source of both classes of lipid mediators. Under 
inflammatory conditions neutrophils40, 41 and macrophages35, 42 preferentially synthesize LTB4 and PGE2 
over MaR1 and RvD2. Also endothelial43 and epithelial cells44 add to the pool of LTB4 and PGE2 
production. Upon a switch towards resolution, macrophages (reparative) as well as neutrophils (possibly 
second wave neutrophils) also synthesize Maresin-18 and Resolvin D235, 45. However, during the course of 
a chronic inflammation, such as atherosclerosis, it is likely that overall the inflammatory environment 
prevails, favoring the synthesis of inflammatory lipid mediators. 
 
The observed imbalance of arterial lipid mediators raised the question whether the administration 
of the decreased resolving mediators (MaR1 and RvD2) prompts inhibition of atheroprogression, thus 
possibly disclosing a novel therapeutic concept in the context of atherosclerosis. Although MaR1 and RvD2 
share leukocyte-related functions few observations point out in the direction of distinct roles for these pro-
resolving lipid mediators9. Hence, we have administered a combination of MaR1 and RvD2 as a therapeutic 
approach in our disease model. Indeed mice receiving resolving lipid mediators exhibited lesions with 
stability traits comparable to the baseline group, with additional improved smooth muscle cells numbers, 
collagen content, fibrous cap thickness and increased numbers of reparative macrophages. In line with 
previous reports 5, 6, 8, our in vitro studies confirmed that RvD2 and MaR1 have the ability to skew 
macrophage phenotype towards resolution-like, with increased TGFβ production and secretion. In 
accordance, and much like the lesion phenotype observed in the present study, macrophage-borne TGFβ 
gives rise to lesions characterized by smooth muscle cell accumulation, collagen deposition, and lower 
macrophage numbers46. In vitro, MaR1 and RvD2 reduced the secretion of pro-inflammatory cytokines by 
macrophages, an effect that was earlier reported for Resolvin D217. Hence, overall the actions of Maresin-
1 and Resolvin D2 on macrophages fully support a dampening of the inflammatory milieu within the lesion. 
Resolving lipid mediators are mostly found in self-resolving exudates, suggesting their synthesis by M2 
macrophages.5, 16 In agreement, M2 macrophages produce more pro-resolving lipid mediators than M1.35 
These observations then suggest a positive feedback loop, by the administration of MaR1 and RvD2, that 
further feeds resolution of inflammation and halts atheroprogression. Indeed, positive loops of resolution 
have been previously reported47, such as the stimulation of synthesis of Lipoxin A4 by Resolvin E148. MaR1 
and RvD2-treated mice exhibited lesions with increased levels of collagen, as compared to vehicle-treated 
group. Collagen within the atherosclerotic plaque mainly originates from smooth muscle cells. Despite 
MaR1 and RvD2 being able to directly exert effects on smooth muscle cells23, in the current study, the 
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increased collagen levels observed within the lipid mediator treated-group were explained by direct actions 
of MaR1 and RvD2 on the macrophages, which in turn, by changing the surrounding milieu, stimulated 
collagen production by smooth muscle cells. 
 
Despite the success of lipid-lowering statins, anti-platelet or anti-hypertensive compounds, 
mortality from cardiovascular disease remains high and development of specific plaque stabilization 
therapies is a major challenge in preventive cardiology. The current inflammation focused understanding 
of atherosclerotic plaque destabilization has led to the emergence of numerous pre-clinical developments. 
However, recent examples of obstacles in the clinical phase epitomize the pitfalls inherent to cardiovascular 
drug development. E.g. neutralization of TNF, a signature cytokine released from activated macrophages, 
does not reduce the risk for acute coronary syndrome. There are many such examples available4, showing 
that recent strategies targeting inflammation in the context of plaque destabilization are full of intrinsic 
obstacles and alternative approaches are required. In addition anti‐inflammatory therapies mostly 
antagonize specific pathways engaged upon inflammation, and in spite several ongoing clinical trials and 
their beneficial effects at early stages of inflammation, anti-inflammatory approaches can be 
immunosuppressive and limit repair.29, 49, 50 The transfer of concepts of resolution from bench to bedside 
requires a shift from inhibitory therapy to replacement therapy, i.e. from antagonism to agonism. While 
anti-inflammatory actions are limited to an inhibitory response, pro-resolution involves stimulation and 
initiation of processes such as apoptosis, efferocytosis, changes in macrophage phenotype and repair. 
Moreover, pro-resolution mediators have been associated with positive feedback loops, where one pro-
resolving mediator induces another.47 On the contrary, anti-inflammatory drugs, such as those inhibiting 
COX-2, have been reported to delay resolution of inflammation, by disrupting the production of anti-
inflammatory prostaglandins and lipoxins 51-54. Thus, our study is in support of the potential translational 
relevance of resolution-inducing agonists in cardiovascular disease progression. 
 
In summary, delivery of resolving lipid mediators halts inflammation possibly by instructing a 
positive feed-back loop centered on the induction of reparative macrophages giving rise to a homeostasis-
restoring environment promoting plaque stability. 
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FIGURE LEGENDS 
 
Figure 1: Imbalance of aortic lipid mediators fosters atheroprogression. Apoe-/- mice were fed a high 
fat diet for 4 weeks, 8 weeks or 4 months and inflammatory (A) or resolving (B) lipid mediators were 
quantified in aortic lipid extracts using liquid chromatography and tandem mass spectrometry (LC-
MS/MS). Representative chromatographs for Resolvin D2 and Maresin 1 at 4 weeks and 4 months are 
displayed (C). Data are expressed as mean±SEM. One way ANOVA with Tukey’ multiple comparison test. 
* p<0.05, ** p<0.01, *** p<0.001 compared to 4 weeks high fat diet. n=24 aortas for 4 weeks high fat diet, 
16 for 8 weeks and 19 for 4 months high fat diet. LTB4, Leukotriene B4; MaR1, Maresin 1; PGA1, 
Prostaglandin A1; 8iso-PGA2, 8iso-Prostaglandin A2; PGD2, Prostaglandin D2; PGE2, Prostaglandin E2; 
15d-PGJ2, 15-deoxy-Δ12,14-Prostaglandin J2; RvD2, Resolvin D2. 
 
Figure 2: Aortic lipid mediators correlate with signs of plaque stability. Apoe-/- mice were fed a high 
fat diet for 4 months and lipid mediators were quantified in aortic lipid extracts using liquid chromatography 
and tandem mass spectrometry. Lipid mediator levels were correlated with atherosclerotic lesion 
characteristics assessed in aortic root sections of the same mice: lesion size (HE staining), macrophage 
number (Mac2 staining), endothelial activation (endothelial ICAM1 and VCAM1 staining), necrotic core 
size (HE staining), smooth muscle cell numbers (αSMA staining), collagen amount (Sirius red staining), 
and fibrous cap thickness (Sirius red staining). Displayed are radar charts where the axis represents the 
Pearson correlation coefficient r (-1 indicates maximal negative correlation, 0 indicates no correlation, +1 
maximal positive correlation) for each lesion characteristic. Axes are only labelled when a significant 
correlation (p≤0.05) was found. Shown are radar charts for Prostaglandin E2 (PGE2, A), Leukotriene B4, 
(LTB4, B), Maresin 1 (MaR1, C), and Resolvin D2 (RvD2, D). Detailed explanation of figure outline is 
displayed in (E). Representative images for HE staining, Sirius red staining, Mac2 staining, and αSMA 
staining of plaques obtained from mice with high amount of inflammatory lipid mediators (top) or with 
high amount of resolving lipid mediators (bottom) are shown in (F). Note that different intensities in HE 
and Sirius red staining do not impact on quantification, as area and not intensity is measured. Black scale 
bars indicate 200 µm, white scale bars indicate 50 µm. Data are calculated as Pearson correlation from 19 
mice.  
 
Figure 3: Treatment with Resolvin D2 and Maresin 1 prevents atheroprogression. (A) Experimental 
outline. Apoe-/- mice were fed a high fat diet. After three months the baseline group was harvested. The 
remaining two groups received high fat diet for another month. During this time one group was treated with 
PBS while the other group was treated with a combination of RvD2 and MaR1 (each 100 ng/mouse, i.p., 
every second day, last 4 weeks of high fat diet feeding) (B) Atherosclerotic lesion size. (C) Necrotic core 
size. (D) Lesional collagen. (E) Fibrous cap thickness. (F) Quantification of smooth muscle cells. (G) 
Display of lesion macrophage counts. (H) Calculation of vulnerability plaque index (VPI). (I) 
Representative images of HE staining, Sirius red staining, αSMA staining, and Mac2 staining are displayed. 
Black scale bars indicate 200 µm, white scale bars indicate 50 µm. One way ANOVA with Tukey’ multiple 
comparison test was used to calculate statistical significance. *p<0.05, **p<0.01, ***p<0.001, n.s. not 
significant, HFD, high fat diet; MaR1, Maresin 1; RvD2, Resolvin D2; HE, hematoxylin and eosin stain. 
 
Figure 4: Resolvin D2 and Maresin 1 induce a pro-resolving macrophage phenotype. (A-B) Apoe-/- 
mice were fed a high fat diet for four months. During the last month mice were treated with PBS or a 
combination of RvD2 and MaR1 (each 100 ng/mouse, every second day, i.p.). Lesions of MaR1 and RvD2-
treated mice are characterized by a pro-resolving macrophage phenotype. (A) Macrophages (CD68) in 
aortic root sections were costained with antibodies to iNOS (inflammatory) or CD206 (reparative). 
Representative images show CD68/CD206 double staining. Scale bar indicates 50µm. (B) mRNA 
expression of macrophage markers Nos2 (inflammatory) and Retnla (reparative) in the aortas of treated 
mice. Data are expressed as mean±SEM. Unpaired t-test was used. n=16-17. (C-D) TNF/IFNγ-activated 
macrophages were treated with MaR1 and RvD2 and the cell supernatant was collected to assess cytokine 
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secretion (C) while the cells were harvested for mRNA expression (D). (C) Cytokine secretion of MaR1 
and RvD2-treated macrophages in relative to TNF/IFNγ-activated macrophages (set to 1 for each cytokine, 
dashed line). Data are expressed as mean±SEM. Wilcoxon Signed-rank test. n=7. (D) Fold changes in 
mRNA expression of TNF/IFNγ-activated macrophages following addition of MaR1 and RvD2. Data are 
expressed as mean±SEM. Wilcoxon Signed-rank test. n=4-10. (E-G) MaR1 and RvD2-treated macrophages 
instruct smooth muscle cells to produce collagen. (E) mRNA expression in TNF-activated aortic smooth 
muscle cells in presence or absence of MaR1 and RvD2. Dashed line represents non-treated smooth muscle 
cells set to 1. (F) mRNA expression in aortic smooth muscle cells treated with the supernatant of TNF-
activated macrophages (TNFsup) or macrophages activated with TNF in presence of MaR1 and RvD2 
(MaR1/RvD2sup). Expression is shown as fold change in relation to treatment with the supernatant of non-
activated macrophages set to 1. (G) Collagen production assessed by absorbance of Sirius red. Aortic 
smooth muscle cells were treated as described in (E). In some experiments SB431542 (10μM) was present 
to inhibit TGFβ receptor. Results are shown as fold change in relation to smooth muscle cells treated with 
the supernatant of untreated macrophages set to 1. Data are expressed as mean±SEM. Mann Whitney test 
was used to compare indicated groups. n=4-6 for each bar  
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Novelty and Significance 
 
What Is Known? 
 
 Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) the precursors of resolving lipid 
mediators, have been shown to be atheroprotective. 
 
 Atherosclerotic lesions exhibit features of failed inflammation resolution. 
 
 Resolving lipid mediators are important regulators of resolution of inflammation. 
 
 
What New Information Does This Article Contribute? 
 
 Inflammatory lipid mediators Leukotriene B4 (LTB4) and Prostaglandin E2 (PGE2) directly 
correlate with traits of plaque vulnerability whereas resolving lipid mediators Resolvin D2 (RvD2), 
and Maresin 1 (MaR1) directly correlate with plaque stability. 
 
 In an atheroprogression mouse model, RvD2 and MaR1 induce plaque stability by favoring a 
reparative macrophage phenotype accompanied by a decrease of lesional macrophage 
accumulation, and an increase in smooth muscle cells. 
 
 RvD2 and MaR1 shift the profile of lesional macrophages from inflammatory to reparative, 
favoring a pro-resolution milieu, with increased TGFβ levels and decreased TNF and IL6. 
 
 RvD2 and MaR1-treated macrophages instruct smooth muscle cells to produce collagen. 
 
 The administration of RvD2 and MaR1 prevents atheroprogression suggesting these mediators as 
potential therapeutic candidates to avert plaque destabilization. 
 
 
 
As a chronic inflammation, atherosclerosis also exhibits signs of failed resolution, a process which is 
determined by a switch in the lipid mediator class. Resolving lipid mediators, the derivatives from 
docosahexaenoic and eicosapentaenoic fatty acids, actively orchestrate resolution of inflammation. Clinical 
and animal model studies attribute protective features docosahexaenoic and eicosapentaenoic fatty acids in 
atheroprogression, which positively correlate with decreased inflammation and increased plaque stability. 
However, the actions of docosahexaenoic and eicosapentaenoic in atherosclerosis are poorly understood. 
The current study evidences, in a murine atheroprogression model, an imbalance between inflammatory 
and resolving lipid mediators that hinders resolution of inflammation. Inflammatory Leukotriene B4 and 
Prostaglandin E2 directly associate with increased macrophage accumulation, decreased collagen 
deposition and smooth muscle cell number, all traits of plaque instability. On the contrary, administration 
of resolving mediators Maresin 1 and Resolvin D2 in a murine model of atheroprogression results in 
increased lesional plaque stability. Atherosclerotic plaques of treated mice presented decreased macrophage 
accumulation, increased numbers of smooth muscle cells as well as collagen deposition. Moreover, in these 
lesions, the macrophage phenotype was primarily reparative. In vitro studies show that Maresin 1 and 
Resolvin D2 induce a pro-resolving phenotype in macrophages that then secrete less TNF and IL6 while 
increasing the TGFβ release. Interestingly, the macrophage secretome in turn acts on smooth muscle cells, 
stimulating collagen production. Taken together our data suggest that treatment with Maresin 1 and 
Resolvin D2 halts atheroprogression and promotes lesion stability.  
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Supplementary methods 30 
 31 
Mice 32 
Apoe
-/-
 mice on C57Bl/6 background were fed a high-fat diet (HFD) containing 21% fat (ssniff) for 4 33 
or 8 weeks, 3 months, or 4 months as indicated in the respective experimental description. For 34 
treatment studies, after 3 months HFD, 100ng of MaR1 and 100ng of RvD2, or vehicle, were 35 
administered, i.p, every second day, for a period of 4 weeks. Lipid mediators’ dosage and treatment 36 
regimen is based on earlier reports 
1
 and supported by comparable studies
1, 2
. At the end of the feeding 37 
period, the body weight of the mice was measured and mice were euthanized by an overdose of 38 
ketamine/xylazine. All animal experiments were approved by the local ethical committee.  39 
 40 
Plasma cholesterol and triglyceride measurements 41 
Cholesterol and triglyceride levels in mouse plasma were quantified using enzymatic assays 42 
(Roche/Hitachi) according to the manufacturer’s protocol.  43 
 44 
Assessment of blood cell counts 45 
Blood leukocyte counts were quantified by flow cytometry. Staining of single cell suspensions of 46 
blood was conducted using combinations of antibodies specific for CD115‐PE (eBioscience, AFS98), 47 
CD11b-PerCP (BD, M1/70), CD45‐APC‐Cy7 (BD, 30‐F11), Gr1‐APC (eBioscience/BD, RB6‐8C5) 48 
and CD3-FITC (eBioscience, 145-2C11). Before cell staining, red blood cell lysis was performed 49 
using appropriate volume of lysis buffer (150 mM NH4Cl; 10 mM KHCO3; 0.1 mM diNaEDTA, pH 50 
7.4). Cells were washed with Hanks Balanced Salt Solution (HBSS) and directly analyzed by flow 51 
cytometry using a FACSCantoII (BD). Absolute cell numbers were assessed by use of CountBright™ 52 
absolute counting beads (Invitrogen). Data were analyzed with FlowJo Software (Tree Star Inc.). 53 
Erythrocytes were quantified by blood counter (ScilVet abc Plus analyser). 54 
 55 
Immunohistochemistry  56 
The extent of atherosclerosis was assessed in aortic roots after Hematoxylin and Eosin (HE) staining 57 
followed by computerized image analysis and quantification (Leica Qwin Imaging software). 58 
Minimum fibrous cap thickness (FCT) was defined as the minimum distance between the necrotic core 59 
and the arterial lumen, and measured in HE stained sections. Total collagen was quantified (Fiji, 60 
Image J software) after Sirius red staining, as a measure of Sirius red positive area within plaque 61 
lesion. Aortic roots were stained with antibodies to Mac2 (Cedarlane), VCAM1 (429, BD 62 
Biosciences), or ICAM1 (3E2, BD Biosciences), smooth muscle cell actin (1A4, Sigma-Aldrich), 63 
CD68 (Abcam), iNOS (Cell signaling), or CD206 (MR5D3, BioRad). Nuclei were counter-stained by 64 
4',6-Diamidino-2-phenylindol (DAPI). A Leica DM4000 microscope with a 25x objective (Leica 65 
Microsystems) and a Leica DFC 365FX camera were used to capture images. Leica Qwin Imaging 66 
software (Leica Ltd.) was employed for image analysis. Vulnerability plaque index (VPI) was used to 67 
evaluate the overall degree of instability. The formula for VPI was expressed as VIc(i)= (U(i)/S(i)) 68 
where i represents each studied mouse.  U includes the sum of necrotic core area (% of intima) and 69 
Mac2
+
 area (% of intima). S consists of SMA
+
 area (% of intima) and collagen
+
 area (% of intima).  70 
 71 
Chemicals 72 
6-keto-prostaglandin F1α (6kPGF1α), thromboxane B2 (TXB2), prostaglandin E2 (PGE2), 73 
prostaglandin A1 (PGA1), 8-iso prostaglandin A2 (8-iso PGA2), prostaglandin E3 (PGE3), 15-deoxy-74 
Δ12,14-Prostaglandin J2 (15d-PGJ2), lipoxin A4 (LxA4), lipoxin B4 (LxB4), lipoxin A4 deuterated 75 
(LxA4-d5), resolvin D1 (RvD1), resolvin D2 (RvD2), 7(S)-maresin (7-MaR1), leukotriene B4 76 
(LTB4), leukotriene B5 (LTB5), leukotriene B4 deuterated (LTB4-d4), 10(S),17(S)-protectin (PDx), 77 
18-hydroxyeicosapentaenoic acid (18-HEPE), dihydroxy-eicosatetraenoic acid (5,6-DiHETE), 15-78 
hydroxyeicosatetraenoic acid (15-HETE) and 12-HETE, 8-HETE, 5-HETE, 5-HETE-d8, 17-hydroxy-79 
docosahexaenoic acid (17-HDoHE) and 14-HDoHE, 14,15-epoxyeicosatrienoic acid (14,15-EET) and 80 
11,12-EET, 8,9-EET, 5,6- EET, 5-oxoeicosatetraenoic acid (5-oxoETE) were purchased from Cayman 81 
Chemicals (Ann Arbor, MI, USA). 82 
 83 
 84 
 85 
Aorta and plasma lipid extraction 86 
Mouse aorta were crushed with a FastPrep®-24 Instrument (MP biomedical) in 200 µL of HBSS 87 
(Invitrogen) and 5 µL of internal standard mixture (LxA4-d5, LTB4-d4 and 5-HETE-d8 at 400 ng/mL 88 
in methanol, MeOH). After 2 crush cycles (6.5 m/s, 30 s), 10µL was withdrawn for protein 89 
quantification and 300 µL of cold MeOH was added. Samples were centrifuged at 3000 rpm for 15 90 
min at 4°C. Supernatants were collected, completed to 2 mL in H2O and submitted to solid-phase 91 
extraction using HRX-50 mg 96-well (Macherey Nagel). Briefly, the plate was conditioned by 92 
successive washing with MeOH (2 mL) and H2O/MeOH (90:10, 2 mL). The sample was loaded at 93 
flow rate of 0.1 mL/min. After complete loading, the plate was washed with H2O/MeOH (90:10, 2 94 
mL). After drying under aspiration, lipid mediators were eluted with MeOH (2 mL). Solvent was 95 
evaporated under nitrogen and samples were dissolved with MeOH and stored at -80 °C for liquid 96 
chromatography/tandem mass spectrometry measurements. 97 
 98 
Liquid chromatography/tandem mass spectrometry measurements 99 
By this technique we performed the quantification of 6kPGF1α, TXB2, PGE2, PGA1, 8-isoPGA2, 100 
PGE3, 15d-PGJ2, LxA4, LxB4, RvD1, RvD2, 7-MaR1, LTB4, LTB5, PDx, 18-HEPE, 5,6-DiHETE, 101 
15-HETE, 12-HETE, 8-HETE, 5-HETE, 17-HDoHE, 14-HDoHE, 14,15-EET, 11,12-EET, 8,9-EET, 102 
5,6-EET and 5-oxo-ETE in aortas
3
. To simultaneously separate lipids of interest and deuterated 103 
internal standards, LC-MS/MS analysis was performed on UHPLC system (Agilent LC1290 Infinity) 104 
coupled to Agilent 6460 triple quadrupole MS (Agilent Technologies) equipped with electro-spray 105 
ionization operating in negative mode. Reverse-phase UHPLC was performed using ZorBAX SB-C18 106 
column (2.1 mm, 50 mm, 1.8 µm) (Agilent Technologies) with a gradient elution. The mobile phases 107 
consisted of water, ACN and FA (75:25:0.1;v/v/v) (A) and ACN, FA (100:0.1, v/v) (B). The linear 108 
gradient was as follows: 0% B at 0 min, 85% B at 8.5 min, 100% B at 9.5 min, 100 % B at 10.5 min 109 
and 0 % B at 12 min. The flow rate was 0.35 mL/min. The autosampler was set at 5°C and the 110 
injection volume was 5 mL. Data were acquired in Multiple Reaction Monitoring (MRM) mode with 111 
optimized conditions (ion optics and collision energy). Peak detection, integration and quantitative 112 
analysis were done using Mass Hunter Quantitative analysis software (Agilent Technologies). For 113 
each standard, calibration curves were built using 10 solutions at concentration ranging from 0.95 114 
ng/mL to 500 ng/mL. A linear regression with a weight factor of 1/X was applied for each compound. 115 
The limit of detection (LOD) and the limit of quantification (LOQ) were determined for the 27 116 
compounds using signal to noise ratio (S/N). The LOD corresponded to the lowest concentration 117 
leading to a signal to noise over 3 and LOQ corresponded to the lowest concentration leading to a 118 
signal to noise over 5. All values under the LOQ were not considered. Importantly, blank samples 119 
were evaluated, and their injection showed no interference (no peak detected), during the analysis. 120 
Hierarchical clustering and heat-map were obtained with R (www.r-project.org). PUFA metabolite 121 
quantities were transformed to z-scores and clustered based on 1-Pearson correlation coefficient as 122 
distance and the Ward algorithm as agglomeration criterion. 123 
 124 
Microarray analysis 125 
Aortas were homogenized in 500 µL of TRIzol reagent (ambion, Life Technologies) with a T10 basic 126 
Ultra Turrax disperser homogenizer (IKA). Nucleic acids were separated by addition of 100 µL 127 
Chloroform (Sigma Aldrich) followed by centrifugation, and subsequently precipitated with 99% 128 
ethanol and loaded into a RNA microprep purification column (Zymo Reseacrh) to proceed with 129 
purification according to manufacturer’s instructions. RNA quality and concentration was assessed on 130 
Nanodrop 2000 (Thermo Scientific). Transcriptome studies were run in an Affymetrix GeneChip® 131 
Mouse Transcriptome 1.0 Arrays used in combination with random priming and a one-color based 132 
hybridization protocol. Microarray signals were detected using the Affymetrix GeneChip® 3000 133 
Scanner.  134 
 135 
Bioinformatics 136 
Three replicates of PBS- and RvD2/MaR1-treated samples were analyzed using standard protocols 137 
(RMA) to compute gene-wise fold changes (fc) between the conditions and the respective p-values. 138 
With the limited number of macrophages in whole aortas, only small fold changes were expected for 139 
even large differences in the macrophage population in the two conditions. In order to test whether our 140 
data supports a shift towards M2 macrophages in the treated samples we compared the profiles with 141 
data from a recent study defining gene profiles of macrophage polarization
4
. In this study (GEO data 142 
set GSE69607, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69607), 600-700 up- and 143 
down-regulated genes in M1 and about 400 each up- and down-regulated genes in M2 were identified. 144 
A signature of genes was defined highly discriminating between M1 and M2 macrophages consisting 145 
of 210 genes from the Jablonski data via a fold-change threshold of log2(fc) > 1.5 (about 3-fold) and a 146 
p-value < 0.05. We then compare these 210 genes with our fold change data and identified subsets of 147 
M1/M2 discriminating genes (signatures), which changed similarly in our data sets (Online Figure 148 
VII). For this we computed dot product scores for genes from subsets of different sizes. The dot 149 
product scores for the signature genes in our data are significantly higher as compared to their score in 150 
50 similar microarray measurements randomly selected from GEO. 151 
 152 
ELISA 153 
Plasma and cell supernatant TGFβ1, TNF, IL-6 and IL-13 were assessed by a commercially available 154 
Luminex assay (Affymetrix) according to the manufacturer’s protocol. Plasma serum amyloid A 155 
(SAA) was measured by ELISA (ICL lab). 156 
 157 
In vitro studies 158 
Peritoneal macrophages were plated at 80% confluence and allowed to adhere for 3h. Cells were 159 
washed and treated with TNF (10 ng/ml) and IFNγ (20 ng/ml), in presence or absence of MaR1 and 160 
RvD2 (10 nM) for 14h. The cell supernatant was collected and immediately frozen. Cells were further 161 
washed with PBS, lysed, and treated according to manufacturer’s protocol for RNA isolation (Quick-162 
RNA
TM
 MicroPrep, Zymo Research). Expression of genes of interest was assessed on samples’ cDNA 163 
(QuantiNova Reverse Transcriptase kit, Qiagen), on an Applied Biosystems HD 7900 system, and 164 
analysed by the ΔΔCT method. Primers and polymerase (QuantiNova SYBR Green PCR kit) were 165 
purchased from Qiagen. 166 
MOVAS (murine vascular aortic smooth muscle cells) were cultured at 80% confluence and 167 
serum-starved overnight. Cells were treated with TNF (10 ng/ml) for 2 hours and thereafter with 168 
MaR1 and RvD2 (10nM) for 14h. Alternatively, cells were starved overnight and treated with 169 
supernatant from peritoneal macrophage (untreated, TNF/IFNγ-treated or TNF/IFNγ/MaR1/RvD2) for 170 
14h. Cells were harvested for RNA preparation as supra described. mRNA expression was analysed 171 
by the ΔΔCT method. For collagen analysis in MOVAS, cells were starved overnight, and treated with 172 
macrophage cell supernatant for 24 h, as supra described. For TGFβ receptor inhibition studies, 173 
smooth muscle cells were treated with SB431542 (Tocris) (10μM) for 2h prior to treatment with 174 
macrophage cell supernatant containing SB431542 (10μM). Collagen was stained as previously 175 
reported.
5
 Briefly, cells were washed with PBS, fixed with 4% PFA, stained with 0.1% Sirius red in 176 
0.1M picric acid, and thereafter lysed with 0.01 M NaOH. Collagen was analysed by absorption 177 
measured on a standard plate reader at 550nm.  178 
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Online Figure I: Resolvin D2 and Maresin 1 treatment does not affect endothelial ICAM1 and 203 
VCAM1 expression. Apoe
-/-
 mice were fed a high fat diet for four months. During the last four weeks 204 
of diet mice were injected with PBS or a combination of Maresin 1 (MaR1) and Resolvin D2 (RvD2) 205 
(each 100 ng/mouse, every second day, i.p.). Aortic root sections were stained for ICAM1 or VCAM1. 206 
All values are displayed as mean±SEM. Unpaired t-test. n=16 for PBS group and 17 for RvD2/MaR1 207 
group.  208 
 209 
Online Figure II: Resolvin D2 and Maresin 1 treatment does not affect body weight and plasma 210 
lipid levels. Apoe
-/-
 mice were fed a high fat diet for four months. During the last four weeks of diet 211 
mice were injected with PBS or a combination of Maresin 1 (MaR1) and Resolvin D2 (RvD2) (each 212 
100 ng/mouse, every second day, i.p.). At the end of the high fat diet feeding body weight was 213 
assessed (A), and cholesterol (B) and triglycerides (C) were measured in the plasma. All values are 214 
displayed as mean±SEM. Unpaired t-test. n=16 for PBS group and 17 for RvD2/MaR1 group.  215 
 216 
Online Figure III: Resolvin D2 and Maresin 1 treatment does not affect blood cell counts. Apoe
-/- 217 
mice were fed a high fat diet for four months. During the last four weeks of diet mice were injected 218 
with PBS or a combination of Maresin 1 (MaR1) and Resolvin D2 (RvD2). Blood was drawn at the 219 
end of the high fat diet feeding and erythrocytes (A), lymphocytes (B), neutrophils (C), classical 220 
monocytes (D), and non-classical monocytes (E) were quantified. All values are displayed as 221 
mean±SEM. Unpaired t-test. n=16 for PBS group and 17 for MaR1/RvD2 group.  222 
 223 
 224 
Online Figure IV: Resolvin D2 and Maresin 1 treatment does not affect spleen and bone marrow 225 
(BM) cell counts. Apoe
-/- 
mice were fed a high fat diet for four months. During the last four weeks of 226 
diet mice were injected with PBS or a combination of Maresin 1 (MaR1) and Resolvin D2 (RvD2). 227 
Spleen (A-D) and bone marrow (E-H) were collected and homogenized or flushed, respectively. Red 228 
blood cells were lysed, and cells were quantified: spleen (A) and BM (E) lymphocytes, classical (B, F) 229 
and non-classical (C, G) monocytes, and neutrophils (D, H). All values are displayed a mean±SEM. 230 
Unpaired t-test. n=16 for PBS group and 17 for RvD2/MaR1 group.  231 
 232 
Online Figure V: Resolvin D2 and Maresin 1 treatment does not affect lymph nodes counts. 233 
Apoe
-/- 
mice were fed a high fat diet for four months. During the last four weeks of diet mice were 234 
injected with PBS or a combination of Maresin 1 (MaR1) and Resolvin D2 (RvD2). Inguinal, axillary, 235 
lumbar, and mesenteric lymph nodes (LN) were collected, homogenized and analyzed for counts of 236 
lymphocyte subpopulations. All values are displayed a mean±SEM. Unpaired t-test. n=16 for PBS 237 
group and 17 for RvD2/MaR1 group. 238 
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Online Figure VI: Effect of Resolvin D2 and Maresin 1 treatment on plasma cytokines and 240 
serum amyloid A. Apoe
-/- 
mice were fed a high fat diet for four months. During the last four weeks of 241 
diet mice were injected with PBS or a combination of Maresin 1 (MaR1) and Resolvin D2 (RvD2). 242 
Plasma was collected and IL-6 (A), IL-13 (B), TNF (C), TGFβ (D), serum amyloid A (SAA) (E) were 243 
assessed by ELISA. All values are displayed as mean±SEM. Unpaired t-test. n=16 for PBS group and 244 
17 for RvD2/MaR1 group.  245 
 246 
 247 
Online Figure VII: Resolvin D2 and Maresin 1 treatment induces an M2 macrophage 248 
polarization gene expression signature in aortas. Plot shows the correlation of fold changes 249 
computed for the genes in the Jablonski et al.
4
 data (blue line) and in our data set (black). Shown are 250 
absolute fold changes (left) and relative fold changes (right), i.e. actual fold changes as fractions of the 251 
sum of the 50 fc values (the 50 gene fold change vector has been normed to 1). Most signature genes 252 
(43) are down-regulated in M2 macrophages (when compared to M1 macrophages) and RvD2/MaR1-253 
treated aortas (compared to PBS treatment), whereas only 7 are up-regulated.   254 
 255 
Online Figure VIII: During atherosclerosis progression macrophages accumulate in the lesion 256 
and an inflammatory macrophage phenotype is favored. Apoe
-/-
 mice were fed a high fat diet for 257 
four weeks or four months. Atherosclerotic lesions in the artic root were analyzed for macrophage 258 
content (Mac2 staining) and phenotype (iNOS, M1, and CD206, M2). (A) Lesional macrophage 259 
content. (B) Relative numbers of iNOS
+
 M1 macrophages and CD206
+
 M2 macrophages. (C) Ratio of 260 
M1 and M2 macrophages after 4 weeks and 4 months of high fat diet. All values are displayed as 261 
mean±SEM. Unpaired t-test. n=9-15.  262 
 263 
 264 
Online Figure IX. Suggested mechanism of action of MaR1/RvD2 in halting atheroprogression. 265 
Maresin 1 (MaR1) and Resolvin D2 (RvD2) act on lesional macrophages, inducing phenotype changes 266 
towards a reparative phenotype. These reparative macrophages reduce the inflammatory environment 267 
by enhanced secretion of TGFβ and decreasing the concentrations of secreted IL6 and TNF. The 268 
resolving milieu aids to decreased macrophage accumulation and smaller necrotic core sizes, and 269 
instructs smooth muscle cells to produce collagen, resulting in fibrous cap thickening and increased 270 
plaque stability.  271 
 PGE2 PGD2 PGA1 8iso-
PGA2 
LTB4 15d-
PGJ2 
RvD2 MaR1 
Lesion r=0.56 r=0.19 r=-0.12 r=0.21 r=0.58 r=-0.28 r=0.33 r=-0.02 
size p=0.01 p=0.45 p=0.61 p=0.39 p=0.01 p=0.24 p=0.18 p=0.93 
macrophages r=0.38 r=-0.15 r=-0.11 r=0.18 r=0.61 r=0.05 r=-0.14 r=-0.60 
 p=0.02 p=0.55 p=0.65 p=0.47 p<0.01 p=0.85 p=0.59 p<0.01 
SMC r=-0.43 r=0.28 r=0.12 r=0.21 r=-0.48 r=0.22 r=0.63 r=0.51 
 p=0.05 p=0.7 p=0.87 p=0.92 p=0.2 p=0.17 p<0.01 p=0.02 
ICAM1
+
 EC r=0.0 r=-0.37 r=0.39 r=-0.35 r=0.30 r=-0.13 r=-0.24 r=-0.22 
lining p=1 p=0.12 p=0.10 p=0.12 p=0.21 p=0.60 p=0.36 p=0.36 
VCAM1
+
 EC r=0.10 r=-0.27 r=-0.36 r=0.03 r=0.05 r=-0.06 r=0.01 r=-0.66 
lining p=0.67 p=0.27 p=0.13 p=0.89 p=0.83 p=0.81 p=0.99 p<0.01 
Necrotic core r=-0.02 r=-0.28 r=-0.16 r=0.12 r=0.22 r=0.05 r=-0.46 r=-0.82 
size p=0.95 p=0.24 p=0.49 p=0.61 p=0.35 p=1 p=0.04 p<0.01 
Collagen r=-0.78 r=-0.42 r=-0.25 r=-0.16 r=-0.27 r=-0.11 r=0.48 r=0.55 
 p<0.01 p=0.12 p=0.30 p=0.53 p=0.26 p=0.65 p=0.04 p=0.03 
Fibrous cap r=-0.43 r=0.19 r=-0.25 r=-0.32 r=-0.49 r=-0.32 r=0.53 r=0.61 
thickness p=0.06 p=0.46 p=0.19 p=0.21 p=0.02 p=0.22 p=0.04 p=0.01 
Vulnerability r=0.63 r=0.39 r=0.33 r=0.56 r=0.48 r=0.17 r=-0.62 r=-0.72 
Plaque index p<0.01 p=0.21 p=0.14 p=0.53 p=0.01 p=0.38 p<0.01 p<0.01 
 272 
Online Table I: Aortic lipid mediators correlate with signs of plaque stability. Apoe
-/-
 mice were 273 
fed a high fat diet for 4 months and lipid mediators were quantified in aortic lipid extracts using liquid 274 
chromatography and tandem mass spectrometry. Assessed were Prostaglandin E2 (PGE2), 275 
Prostaglandin D2 (PGD2), Leukotriene B4 (LTB4), 15-deoxy-Δ12,14-Prostaglandin J2 (15d-PGJ2),  276 
8iso-Prostaglandin A2 (8iso-PGA2), Prostaglandin A1 (PGA1), Resolvin D2 (RvD2), and Maresin 1 277 
(MaR1). Lipid mediators were correlated with atherosclerotic lesion characteristics assessed in aortic 278 
root sections of the same mice. Measured parameters include: lesion size (HE staining, %), lesional 279 
macrophage number (Mac2 staining, cells/section), endothelial cell (EC) activation (endothelial 280 
ICAM1 and VCAM1 staining), necrotic core size (HE staining, % of intima), smooth muscle cells 281 
numbers (SMC, αSMA staining, cells/section), collagen amount (Sirius red staining, µm2), and fibrous 282 
cap thickness (Sirius red staining, µm) in aortic root sections.  Pearson correlation coefficient r (-1 283 
indicates maximal negative correlation, 0 indicates maximal negative correlation, +1 maximal positive 284 
correlation) was calculated as a function of aortic lipid mediator and respective lesion criteria. 285 
Significant correlations (p≤0.05) are highlighted in gray. Data are calculated from 19 mice. 286 
Online Table II: Blood, bone marrow and spleen show no differences in the expression of cell 287 
surface markers in cell counts between untreated and treated groups. Apoe
-/-
 mice were fed a high 288 
fat diet for 4 months and during the last 4 weeks PBS or lipid mediators (MaR1 and RvD2) were 289 
administered (each 100 ng/mouse, every second day, i.p.). Displayed is the MFI of phenotypic 290 
markers of the indicated cell populations harvested from the blood, the bone marrow, or the spleen.  291 
Data are calculated from 17 MaR1- and RvD2-treated mice and 16 vehicle-treated mice. All values are 292 
displayed as mean±SD. 293 
